News
INCY
69.19
+0.90%
0.62
Incyte Corp <INCY.OQ> expected to post earnings of $1.11 a share - Earnings Preview
Incyte Corp. Expected to post earnings of $1.11 a share. The company is expected to report a 6.4% increase in quarterly revenue. Incyte will report results on July 30 for the period ending June 30 2024. Wall Street's median 12-month price target for the company is $77.00.
Reuters · 13h ago
INCYTE CORP <INCY.O>: OPPENHEIMER CUTS TARGET PRICE TO $81 FROM $84
Reuters · 22h ago
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
NASDAQ · 2d ago
INCYTE CORP <INCY.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $84 FROM $80
Reuters · 2d ago
What to Expect From Incyte’s Q2 2024 Earnings Report
Incyte Corporation (INCY) is expected to announce its fiscal second-quarter earnings for 2024 before the market opens on Tuesday, Jul. 30. The biopharmaceutical company has underperformed the S&P 500’s 16.9% gains on a YTD basis. Analysts expect the company to report a profit of $0.97 per share.
Barchart · 3d ago
Agilent (A) Boosts DCG Segment With New ProteoAnalyzer System
NASDAQ · 4d ago
Weekly Report: what happened at INCY last week (0715-0719)?
Weekly Report · 4d ago
Incyte Corp: Statement of changes in beneficial ownership of securities
Press release · 07/17 20:00
Most shorted S&P 500 stocks in June
American Airlines Group (AAL), Albemarle (ALB) and Charter Communications (CHTR) lead the list of most shorted S&P 500 stocks as a percentage of float in June. Short interest in the U.S. Carrier increased by 10.14% since mid-June.
Seeking Alpha · 07/17 13:52
Incyte, Moderna among most shorted S&P 500 healthcare stocks in June
Seeking Alpha · 07/16 17:01
Are Strong Financial Prospects The Force That Is Driving The Momentum In Incyte Corporation's NASDAQ:INCY) Stock?
Incyte's (NASDAQ:INCY) ROE is 14% higher than the industry average. Incyte has a net income growth of 25% over the past five years. The company has a return on equity of 14% and is reinvesting heavily into its business. We look at the company's profitability to assess its ability to generate profits. In cyte's industry average is 16%.
Simply Wall St · 07/16 10:51
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
NASDAQ · 07/16 10:20
U.S. RESEARCH ROUNDUP-BlackRock, Goldman Sachs, Netflix
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. BlackRock, Goldman Sachs and Netflix revise their ratings and targets on Tuesday. Broadcom, Amazon.com and American Tower among companies with new targets. Some of the companies have announced stock splits.
Reuters · 07/16 07:29
INCYTE CORP <INCY.O>: JP MORGAN CUTS TARGET PRICE TO $59 FROM $60
Reuters · 07/16 04:26
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
NASDAQ · 07/15 18:01
Weekly Report: what happened at INCY last week (0708-0712)?
Weekly Report · 07/15 09:17
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
NASDAQ · 07/12 10:20
We Did The Math XLV Can Go To $161
NASDAQ · 07/11 11:53
Company News for July 10, 2024
NASDAQ · 07/10 13:29
BUZZ-U.S. STOCKS ON THE MOVE-Helios Technologies, Indivior, Principal Financial
The S&P 500 and the Nasdaq hovered at record highs on Tuesday. The Dow Jones Industrial Average was up 0.13% at 39,395.82. Federal Reserve Chair Jerome Powell testified before Congress. The top three Nasdaq percentage gainers were Nvidia and Tesla. Helios Technologies, Indivior and Principal Financial were among the top losers.
Reuters · 07/09 18:11
More
Webull provides a variety of real-time INCY stock news. You can receive the latest news about Incyte Corp through multiple platforms. This information may help you make smarter investment decisions.
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.